Will medications be safer in the future?

Erickson, Amy K.
November 2010
Pharmacy Today;Nov2010, Vol. 16 Issue 11, p40
The article focuses on issues faced by the U.S. Food and Drug Administration (FDA) concerning safety and quality of drugs manufactured abroad. It highlights on the regulatory system implemented by FDA to ensure that products made outside the U.S. meet the standards of the pharmaceutical industry. Also discussed are the changes in drug legislation which includes the inspection of foreign and domestic drug facilities, ban the entry of drugs without documentation, and the recall of unsafe drugs.


Related Articles

  • Risk-Based Thinking in Process Validation. Agalloco, James // Pharmaceutical Technology;Feb2011, Vol. 35 Issue 2, p68 

    The US Food and Drug Administration's draft process-validation guidance changes regulatory expectations by requiring manufacturers to validate their processes by performing enough tests to achieve statistical significance. The author describes why statistical significance, which industry had...

  • Age-Related Disorder. Lowe, Derek B. // Contract Pharma;Jan/Feb2013, Vol. 15 Issue 1, p30 

    The article focuses on disorders associated to aging and the discovery of drugs for these diseases by pharmaceutical companies in the U.S. It notes the scrutiny whether a drugmaker intends to sell medication for unapproved uses. It considers the ability of the Food and Drug Administration (FDA)...

  • The Metrics of Quality Culture. Harrison, Andrew; Schniepp, Susan // Pharmaceutical Technology;Sep2015, Vol. 39 Issue 9, p22 

    The article discusses the guidance for quality metrics proposed by the U.S Food & Drug Administration (USFDA). Topics discussed include passage of the Food and Drug Administration Safety and Innovation Act (FDASIA) to prevent drug shortage, use of the guidance by pharmaceutical industries to...

  • Implementing Process Validation Guidances. Calcott, Peter H. // Contract Pharma;Mar2013, Vol. 15 Issue 2, p54 

    The article discusses how to implement the Process Validation Guidances which was released by the Food and Drug Administration for the pharmaceutical industry in the U.S. It mentions that the rationale and reasoning for process validation is described in the guidance. It describes three...

  • Managing Product Supply Risks. Abraham, Sushil // Pharmaceutical Technology;Apr2012, Vol. 36 Issue 4, p102 

    The article focuses on the use of geographic diversification and legacy technology transfers to deflect drug shortage in the U.S. It mentions that the U.S. Food and Drug Administration, together with the pharmaceutical industry, were asked by U.S. President Barack Obama to provide a solution on...

  • Hot-Topic Roundup.  // Pharmaceutical Technology;Oct2012, Vol. 36 Issue 10, p30 

    The article offers news briefs related to the pharmaceutical industry in the U.S. as of October 2012. The U.S. Food & Drug Administration (FDA) officials are trying to set standards for drugs to reduce prescription drug costs. Pharmaceutical companies are planning to strengthen their position in...

  • Prefillable Syringe Systems. Hlobik, Tibor // Pharmaceutical Processing;Jan2011, Vol. 26 Issue 1, p14 

    The article focuses on the integration of prefillable syringe system in the U.S. market, which gives rise to pressures faced by drug manufacturers concerning their packaging decisions, such as by the U.S. Food and Drug Administration (FDA). It says that prefillable syringe market begun a trend...

  • When the Well Runs Dry. Agres, Ted // Drug Discovery & Development;Oct2011, Vol. 14 Issue 10, p10 

    The article focuses on the bipartisan legislation requiring pharmaceutical manufacturers to provide advance notice to the Food and Drug Administration (FDA) regarding potential shortages in the U.S. It notes that the Preserving Access to Life-Saving Medications Act also allows fines up to 10,000...

  • USP's Response: USP in a Global Era. Williams, Roger L. // Pharmaceutical Technology;Sep2011, Vol. 35 Issue 9, p93 

    In this article the author discusses the issue concerning the globalization of United States Pharmacopeia (USP). He notes that the organization's investments have been focused on the advancement of its laboratories in Maryland, India, China, and Brazil that are all supporting USP's...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics